论文部分内容阅读
总结我院近20年来母婴血型不合112例(ABO 91例,Rh 21例)服用中药新溶Ⅰ号的临床效果。112例分为服药组(研究组)74例,对照组38例。结果表明预防服药明显降低了围产儿死亡率,服药组围产儿死亡率为14‰,对照组105‰,死亡病例均发生在 Rh 血型不合组,其中服药组围产死亡率77‰,对照组为500‰。此药能减轻溶血程度,ABO 血型不合服药组中重度溶血病例占6%,对照组为25%。Rh 血型不合服药组中重度溶血50%,对照组为80%。结果还表明服药期限与治疗效果相关,全部病例中服药期限>10周的重度溶血占12%,服药期限<10周占41%。中药对母血清免疫抗体效价在整个孕期没有升高或有不同程度下降。目前分析表明本药不但对预防 ABO 母婴血型不合有效,而且对 Rh 母婴血型不合也同样有预防性治疗效果。中药新溶Ⅰ号服用方便,无副作用,值得进一步深入研究。
In our hospital over the past 20 years, 112 cases of abortion (ABO 91 cases, Rh 21 cases) take the clinical effect of Chinese medicine Xin Rong Ⅰ. 112 cases were divided into medication group (study group) 74 cases, control group 38 cases. The results showed that preventive medication significantly reduced the perinatal mortality rate, the perinatal mortality rate was 14 ‰ in the medication group and 105 ‰ in the control group. All the deaths occurred in the Rh-incompatible group, in which the perinatal mortality rate was 77 ‰ in the control group 500 ‰. The drug can reduce the degree of hemolysis, ABO blood incompatibility group accounted for 6% of severe hemolytic cases, the control group was 25%. Rh blood incompatibility group severe hemolysis 50%, control group was 80%. The results also showed that the duration of the medication was related to the treatment effect, with 12% of patients taking the drug over a period of> 10 weeks and 41% taking <10 weeks. Chinese medicine on the serum antibody titer throughout the pregnancy did not increase or have varying degrees of decline. The current analysis shows that the drug is not only effective in preventing ABO mother-baby blood group, but also on the mother and child Rh-type incompatibility also have preventive treatment. Chinese medicine new soluble Ⅰ easy to take, no side effects, it is worth further study.